Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
18S rRNA (guanine-N7)-methyltransferase (BUD23) is an *S-adenosyl-L-methionine–dependent* enzyme responsible for introducing a specific N7-methylguanosine mark into 18S rRNA at a conserved residue close to the ribosome's functional core, necessary for proper small subunit assembly and function in eukaryotes[1][5]. Beyond its methyltransferase role, BUD23 acts as a ribosome maturation factor: its presence is required for correct processing of pre-18S rRNA and transition of pre-ribosomal particles from the processome to the pre-40S state, an essential checkpoint in ribosome biogenesis[2][4][5]. BUD23 interacts tightly with the cofactor TRMT112, which is essential for its protein stability and activity[1][3][5]. It is evolutionarily conserved and expressed both in nucleus and cytoplasm, and loss of function severely impairs translation, especially of nuclear-encoded mitochondrial proteins, leading to mitochondrial dysfunction[1]. In humans, BUD23 is also known as WBSCR22, a gene deleted in Williams-Beuren syndrome. Disruption or aberrant expression has been linked to cancer and ribosomopathies; complete loss is embryonic-lethal in mice and causes severe cardiac dysfunction, underlining its critical role in cellular and organismal homeostasis[1].
Inhibitors would block 18S rRNA methylation at G1639 (human)/G1575 (yeast), disrupt ribosome maturation, and impair translation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 18S rRNA (guanine-N7)-methyltransferase (BUD23).